Most adults need just one dose of Prevnar 20. It is not a multi-dose series, and no booster is currently recommended. That single shot covers 20 types of pneumococcal bacteria, making it one of the broadest pneumococcal vaccines available. The details depend on your age, your health, and whether you’ve had any pneumococcal vaccines before.
Who Needs Prevnar 20
The CDC recommends a pneumococcal conjugate vaccine (Prevnar 20 is one option) for two groups of adults: those aged 50 and older who have never received one, and those aged 19 through 49 who have certain medical conditions that raise their risk of pneumococcal disease. Risk conditions include chronic heart, lung, or liver disease, diabetes, alcoholism, smoking, immune-suppressing conditions, cochlear implants, and cerebrospinal fluid leaks.
If you fall into one of these groups and have never received any pneumococcal conjugate vaccine, one dose of Prevnar 20 completes your pneumococcal vaccination. No follow-up doses of any pneumococcal vaccine are needed afterward.
If You’ve Had a Pneumococcal Vaccine Before
Many adults, especially those 65 and older, received an older pneumococcal vaccine at some point. Your prior vaccination history determines whether you need Prevnar 20 and how long to wait before getting it.
Previously received only Pneumovax 23 (PPSV23): You need one dose of Prevnar 20, given at least one year after your most recent Pneumovax shot. After that single dose, your pneumococcal vaccinations are complete.
Previously received only Prevnar 13 (PCV13): You need one dose of Prevnar 20, given at least one year after your Prevnar 13. No additional shots are needed after that.
Previously received both Prevnar 13 and Pneumovax 23: This is where it gets more nuanced. If you’re 65 or older and received both PCV13 (at any age) and PPSV23 (at or after age 65), the decision to get Prevnar 20 is optional and something to discuss with your doctor. The CDC frames this as shared clinical decision-making, meaning the added benefit depends on your individual risk profile.
Dosing for Immunocompromised Adults
Adults with weakened immune systems, cochlear implants, or cerebrospinal fluid leaks follow a slightly different timeline, but the dose count stays the same: one dose. If you’ve previously received both PCV13 and one dose of PPSV23, the CDC recommends waiting at least five years after your most recent pneumococcal vaccine before getting Prevnar 20. After that single dose, no further pneumococcal vaccines are needed.
The longer waiting period for this group reflects the way immune-suppressing conditions affect vaccine response, not a need for extra doses.
What to Expect After the Shot
Side effects from Prevnar 20 are typical of any vaccine and tend to be mild. In clinical trials, younger adults (18 to 59) reported higher rates of side effects than older adults. More than 70% of younger adults experienced pain at the injection site, over 50% had muscle pain, and roughly 40% felt fatigued. Headache affected about 30%, while joint pain and injection site swelling each occurred in more than 10%.
For adults 60 and older, the numbers were lower across the board: injection site pain in over 50%, muscle pain and fatigue each around 30%, and headache in about 20%. In the clinical trials, participants tracked side effects for up to 10 days for local reactions and 7 days for systemic ones like fatigue and muscle aches. Most side effects resolve well within that window.
Cost and Insurance Coverage
Medicare Part B covers pneumococcal vaccines at no cost to you, as long as your provider accepts Medicare assignment. That means no copay, no deductible, and no coinsurance for the shot itself. Most private insurance plans also cover recommended adult vaccines without cost-sharing under the Affordable Care Act’s preventive care provisions. If you’re uninsured, the retail cost of Prevnar 20 can run over $250, so it’s worth checking whether you qualify for any vaccine assistance programs.
Prevnar 20 vs. Other Pneumococcal Vaccines
Prevnar 20 protects against 20 strains of pneumococcal bacteria, a significant jump from Prevnar 13’s 13 strains. A newer option, PCV21, covers 21 strains. Both are conjugate vaccines, which means they trigger a stronger, longer-lasting immune response than older polysaccharide vaccines like Pneumovax 23. Because Prevnar 20 and PCV21 are relatively new, real-world effectiveness data is still being collected. Their approval was based on clinical trials showing they produced immune responses comparable to or better than PCV13.
The practical advantage of choosing Prevnar 20 over older options is simplicity. With the previous approach, some adults needed a two-vaccine sequence (Prevnar 13 followed by Pneumovax 23, spaced months apart). Prevnar 20 consolidates that protection into a single visit.